Dr. Leslie Discusses CAR T-Cell Therapy in MCL

Video

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the developing role of chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the developing role of chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

CAR T-cell therapy is an exciting advancement across lymphoma subtypes, with recently approved constructs in the diffuse large B-cell lymphoma subtype (DLBCL), says Leslie. There are ongoing trials in MCL that show promising efficacy in heavily pretreated patients.

In terms of patients with indolent lymphoma, CAR T-cell therapy is interesting because patients get too sick before they are able to receive the infusion of cells. Although the data are limited, there are excellent results, and patients can stay well enough to receive treatment. Hopefully this can be a curative treatment for this group of patients, Leslie adds.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.